Actively Recruiting
Randomized Controlled Trial of Pancreatic Enzyme Replacement Therapy with Standard Care for Patients with Unresectable Pancreatic Cancer
Led by Hospital Clinico Universitario de Santiago · Updated on 2026-09-21
100
Participants Needed
4
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying patients with unresectable pancreatic cancer that is locally advanced or metastatic, focusing on those who have significant weight loss and a tumor located in the head of the pancreas with a dilated main pancreatic duct. The study evaluates the addition of Pancreatic Exocrine Replacement Therapy PERT alongside the best standard of care, including cancer treatments, diabetes management, acid suppressants, and nutritional support. This is an open-label, randomized, controlled Phase 4 trial lasting up to six months. Participants are randomly assigned to one of two groups. The experimental group receives the best standard of care plus PERT, consisting of Creon 35,000 Ph.U capsules taken three times with main meals and twice with snacks daily for six months. The control group receives the best standard of care alone for the first three months, followed by the addition of PERT at the same dose during an open-label phase for the final three months. All participants take a proton pump inhibitor twice daily while on PERT. During the study, participants are monitored for changes in body weight from the start to six months to evaluate the therapys impact. Researchers also assess adherence to treatments and manage any associated therapies. The trial includes regular visits and evaluations to track progress, safety, and response to the treatment over the six-month period.
CONDITIONS
Brief Title
Efficacy of PERT for PEI in Unresectable Pancreatic Cancer.
Research Team
J
J. Enrique Dominguez-Munoz, PhD, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here